Expanded Access for PSV Personalized Oncolytic Viruses (PSV)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
A compassionate use, expanded access protocol for patients who have exhausted all standard therapy having progressed on chemotherapy and immunotherapy.
Condition or disease
Patients will receive intratumoral or subcutaneous injection of an oncolytic virus called PSV (short for Personalized Virus) every other week until the occurrence of immune related RECIST progression, intolerable toxicity, change to another anti-cancer treatment due to lack of apparent benefit, or personal choice.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Ability to understand and sign a written informed consent form.
Measurable or evaluable disease with least one (1) tumor that is accessible to intratumoral injection.
Eastern Cooperative Group (ECOG) performance status is 0-3 at Screening.
Acceptable liver function at Screening, as evidenced by:
Bilirubin ≤ 3.0 X upper limit of normal (ULN) since this patient has
been diagnosed with Gilbert's Disease
AST (SGOT) and ALT (SGPT) ≤ 5 X ULN.
Serum creatinine < 3 x institution upper limit of normal.
Patient has acceptable hematologic status at Screening, as evidenced by:
Absolute neutrophil count ≥ 1,500 cells/mm3; and
Platelet count ≥ 70,000/mm3; and
Hemoglobin (HGB) ≥ 8.5 g/dL.
Medically acceptable contraception.
Willingness to comply with all protocol procedures, evaluations and rescue measures.
Presence of a serious co-morbid medical condition, or a clinically significant laboratory finding(s) that, in the opinion of the Investigator, suggests the presence of an infectious, endocrine, and/or other inadequately treated systemic disorder.